Search Results - "Barohn, R."

The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors: Matthews, E. Fialho, D. Tan, S. V. et al.

Source: Brain: A Journal of Neurology; Jan2010, Vol. 133 Issue 1, p9-22, 14p, 1 Diagram, 1 Chart, 4 Graphs

Model for the neuromuscular complications of systemic lupus erythematosus.

Authors: Brey, R.L. Cote, S. Barohn, R. et al.

Source: Lupus. Jun1995, Vol. 4 Issue 3, p209-212. 4p.

G.O.20 - Reveglucosidase alfa (BMN 701), a GILT-tagged recombinant human acid alpha glucosidase (rhGAA), evaluation in late-onset Pompe disease: Preliminary clinical efficacy and safety results of an extension study (72-week results).

Authors: Hiwot, T. Barohn, R. Bratkovic, D. et al.

Source: Neuromuscular Disorders. Oct2015 Supplement 2, Vol. 25, pS313-S314. 1p.

Evaluation and treatment of inflammatory myopathies.

Authors: Amato, A. A. Barohn, R. J.

Source: Journal of Neurology, Neurosurgery & Psychiatry. Oct2009, Vol. 80 Issue 10, p9-9. 1p. 2 Color Photographs, 2 Black and White Photographs, 2 Charts.

17PINSPIRE-IBM: an NIH-funded, two-year, multicenter, observational study in inclusion body myositis- an update and AE/SAE reporting.

Authors: Hernandez, I. Wencel, M. Goyal, N. et al.

Source: Neuromuscular Disorders. 2025 Supplement, Vol. 53, pN.PAG-N.PAG. 1p.

16PComparative evaluation of respiratory assessments in inclusion body myositis from INSPIRE-IBM study.

Authors: Hernandez, I. Wencel, M. Goyal, N. et al.

Source: Neuromuscular Disorders. 2025 Supplement, Vol. 53, pN.PAG-N.PAG. 1p.

22O Mexiletine versus lamotrigine in non-dystrophic myotonias – a randomised, double-blinded, cross-over trial.

Authors: Vivekanandam, V. Jayaseelan, D. Skorupinska et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

541P Comparative evaluation of pulmonary function tests and self-reported respiratory function in inclusion body myositis based on NT5c1A antibody serology status.

Authors: Wencel, M. Bjazevic, K. Goyal, N. et al.

Source: Neuromuscular Disorders. 2024 Supplement 1, Vol. 43, pN.PAG-N.PAG. 1p.

48. Statin-associated autoimmune necrotizing myopathy

Authors: Dimachkie, M.M. Muzyka, I.M. Pasnoor, M.K. et al.

Source: Clinical Neurophysiology. Jun2012, Vol. 123 Issue 6, pe30-e30. 1p.

O04 Efficacy of mexiletine in non-dystrophic myotonia: results of an international multi-centred randomised controlled trial

Authors: Rayan, D.L. Raja Matthews, E. Barreto, G. et al.

Source: Neuromuscular Disorders. Mar2012 Supplement, Vol. 22 Issue s1, pS4-S4. 1p.

P27 Genotype-phenotype correlation and longitudinal three year natural history study in the non-dystrophic myotonias in the UK

Authors: Rayan, D.L. Raja Matthews, E. Rajakulendran, S. et al.

Source: Neuromuscular Disorders. Mar2011 Supplement 1, Vol. 21, pS14-S14. 1p.

P71 A randomised, double-blinded, placebo-controlled pilot study assessing the safety and tolerability of Arimoclomol in sporadic inclusion body myositis (IBM)

Authors: Machado, P. Miller, A. Parton, M. et al.

Source: Neuromuscular Disorders. Mar2011 Supplement 1, Vol. 21, pS27-S27. 1p.

P28 Assessing the efficacy of Mexiletine in UK patients with non-dystrophic myotonia

Authors: Rayan, D.L. Raja Matthews, E. Barreto, G. et al.

Source: Neuromuscular Disorders. Mar2011 Supplement 1, Vol. 21, pS14-S14. 1p.

Recurrent neural networks and attention scores for personalized prediction and interpretation of patient-reported outcomes.

Authors: Hu J Kerdabadi MN Mei X et al.

Source: Journal of biopharmaceutical statistics [J Biopharm Stat] 2025 Aug; Vol. 35 (5), pp. 933-943. Date of Electronic Publication: 2025 Mar 13.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9200436 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-5711 (Electronic) Linking ISSN: 10543406 NLM ISO Abbreviation: J Biopharm Stat Subsets: MEDLINE

A 40-week phase 2B randomized, multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of memantine in amyotrophic lateral sclerosis.

Authors: Bhai S Levine T Moore D et al.

Corporate Authors: Bhai S Levine T Moore D et al.

Source: Muscle & nerve [Muscle Nerve] 2025 Jan; Vol. 71 (1), pp. 63-72. Date of Electronic Publication: 2024 Nov 07.

Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II

Journal Info: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE

Rituximab in Newly Diagnosed Generalized Myasthenia Gravis: A New Treatment Paradigm?

Authors: Chuquilin M Barohn R

Source: JAMA neurology [JAMA Neurol] 2022 Nov 01; Vol. 79 (11), pp. 1100-1102.

Publication Type: Editorial; Comment

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE

Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses.

Authors: Miller RG Zhang R Bracci PM et al.

Source: Muscle & nerve [Muscle Nerve] 2022 Jul; Vol. 66 (1), pp. 39-49. Date of Electronic Publication: 2022 Jun 03.

Publication Type: Journal Article; Randomized Controlled Trial

Journal Info: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE

Preface: promoting research in PLS: current knowledge and future challenges.

Authors: Mitsumoto H Turner MR Ajroud-Driss S et al.

Corporate Authors: Mitsumoto H Turner MR Ajroud-Driss S et al.

Source: Amyotrophic lateral sclerosis & frontotemporal degeneration [Amyotroph Lateral Scler Frontotemporal Degener] 2020 Nov; Vol. 21 (sup1), pp. 1-2.

Publication Type: Editorial

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101587185 Publication Model: Print Cited Medium: Internet ISSN: 2167-9223 (Electronic) Linking ISSN: 21678421 NLM ISO Abbreviation: Amyotroph Lateral Scler Frontotemporal Degener Subsets: MEDLINE

Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study.

Authors: Rivner MH Quarles BM Pan JX et al.

Source: Muscle & nerve [Muscle Nerve] 2020 Sep; Vol. 62 (3), pp. 333-343. Date of Electronic Publication: 2020 Jun 10.

Publication Type: Journal Article; Research Support, N.I.H., Extramural

Journal Info: Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 7803146 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-4598 (Electronic) Linking ISSN: 0148639X NLM ISO Abbreviation: Muscle Nerve Subsets: MEDLINE

Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.

Authors: Howard JF Jr Nowak RJ Wolfe GI et al.

Corporate Authors: Howard JF Jr Nowak RJ Wolfe GI et al.

Source: JAMA neurology [JAMA Neurol] 2020 May 01; Vol. 77 (5), pp. 582-592.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE